from Berlin-based Capsulution Nanoscience AG (Capsulution)
will soon be manufactured on an industrial scale.
This is the aim of an agreement reached between Capsulution
and Japanese process engineers Ebara Corporation.
According to the terms of a new license agreement
Ebara will be responsible for the development, manufacture
and joint distribution of facilities for the fully
automatic encapsulation of a wide range of substances
applying the LBL-Technology®.
LBL-Technology® is a high-tech tool for the production
of multi-functional nano- and microcapsules. Because
of their minute dimensions, their diverse functionalities
as well as their highly reproducible production the
capsules are suitable for a wide range of life sciences
applications. Prime objective of the agreed co-operation
with Ebara will be the industrial-scale manufacture
of encapsulations for pharmaceuticals and cosmetics
as well as ingredients for the food industry.
The license agreement
guarantees industrial clients in the near future the
easy handling of LBL-Technology®-based products,
which will lead to a significant market penetration
of the technology. Alongside additional one-off payments
Capsulution will receive variable license fees from
Ebara. “The construction of production facilities
for the industrial-scale manufacture of our nano-capsules
represents a milestone in our company’s history. We
are convinced that together with our renowned partner
Ebara we can now attract many new clients from the
field of life science,” comments Dr. Jörg Mayer,
Chief Engineer of Capsulution and responsible for
the acquisition of new industry partners.
Since its inception
in 2000 Capsulution has pursued the development of
suitable manufacturing techniques for their “intelligent”
nano-capsules as one of the main criterions for success.
The current stage of development together with the
co-operation with Ebara sets Capsulution significantly
apart from many start-up companies in the field of
nanobiotechnology, whose products, quite often, do
not fulfil the requirements for industrial-scale manufacture.
“We are very pleased
with this success. It will certainly aid our recently
started search for new investors,” adds Alexander
Herrmann, Capsulution’s CFO. As of the beginning of
the year Capsulution is offering interested investors
the opportunity to participate in the company. “The
participation of a new investor is a suitable way
to finance our ongoing research and development. For
investors we represent an attractive opportunity to
realise high long-term returns on their investments.“
About Ebara Corp.
With 15,000 employees and a $4.8 billion turnover
in 2004 Ebara is one of the leading Japanese process
engineers. Already back in 1920 the company started
off with the production of centrifugal pumps. Since
then Ebara has been producing in its international
joint ventures and foreign production sites in the
US, Brasil or Italy pumps for water treatment, compressors
and turbines. Expertise gained in vacuum technology
was later successfully applied in the construction
of facilities for semi-conductor production. The company
is advising its clients on the construction of facilities
for environmental protection and carries out environmental
surveys. Alongside its current business divisions
Environmental Technology, Water Treatment and Processing
Plants, and Precision Instruments for Semi-Conductor
Production, Ebara will open up new markets in the
field of Life Science with the help of nanotechnology
“Made in Germany”.
Soucre : http://www.capsulution.com